Shares of major pharmaceutical companies, including Sun Pharmaceutical Industries and Divi’s Laboratories, fell up to 4% after reports that former US President Donald Trump may impose steep tariffs on global drugmakers.
The development has triggered fresh concerns across the pharma sector, especially for companies with significant exposure to the US market.
โ ๏ธ What Triggered the Sell-Off?
- Trump is considering tariffs of 100%โ200% on pharmaceutical imports
- Aim: Shift drug manufacturing back to the US
- Tariffs may apply to companies without pricing agreements or local production
๐ This policy shift has created uncertainty about future revenues for global pharma firms.
๐ Market Reaction
- Pharma stocks declined up to 4% in intraday trade
- The Nifty Pharma index dropped over 5%
- All major pharma stocks traded in the red
๐ Stocks like Biocon, Ipca Labs, and Torrent Pharma also saw sharp declines.
๐ง Why This Matters for Indian Pharma
Indiaโs pharmaceutical sector is highly dependent on exports, especially to the US:
- The US is a key revenue market for Indian drugmakers
- Tariffs could increase costs and reduce competitiveness
- Companies with branded or patented drugs are more exposed
๐ Even the possibility of tariffs is enough to trigger investor panic.
๐ Bigger Risk: Earnings & Growth Impact
- Higher tariffs โ Lower profit margins
- Reduced exports โ Slower revenue growth
- Increased pressure to set up US manufacturing units
๐ Analysts warn that such tariffs could significantly impact earnings if implemented.
๐ Global Impact on Pharma Industry
- Not just Indiaโglobal pharma companies are also at risk
- Supply chains may be disrupted
- Drug prices in the US could increase
๐ The move could reshape the global pharmaceutical industry.
๐ Final Takeaway
- Pharma stocks fell sharply on tariff fears
- Trigger: Trumpโs plan for 100%+ tariffs
- Sector outlook: Uncertain and volatile
๐ Until there is clarity on US policy, pharma stocks may remain under pressure.
